32954834 32102134 33409716 34714275 35982377 36358625 34395246 35264774 32352004 30774754 35050752 32277580 33536188 32624705 34654798 35686110 31243821 34138895 35814226 32677256 30935108 32068118 32164461 35631329 - Search Results

Year	Number of Results
2019	3
2020	9
2021	7
2022	6
2023	1

1

Targeted drug therapy in non-small cell lung cancer: Clinical significance and possible solutions-Part I.

Upadhya A, Yadav KS, Misra A. Upadhya A, et al. Expert Opin Drug Deliv. 2021 Jan;18(1):73-102. doi: 10.1080/17425247.2021.1825377. Epub 2020 Sep 29. Expert Opin Drug Deliv. 2021. PMID: 32954834

2

[Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer].

Qin Q, Ren Y, Zhong D. Qin Q, et al. Zhongguo Fei Ai Za Zhi. 2020 Mar 20;23(3):176-181. doi: 10.3779/j.issn.1009-3419.2020.03.07. Epub 2020 Feb 27. Zhongguo Fei Ai Za Zhi. 2020. PMID: 32102134 Free PMC article. Review. Chinese.

3

Mechanisms of resistance to cyclin-dependent kinase 4/6 inhibitors.

Gomatou G, Trontzas I, Ioannou S, Drizou M, Syrigos N, Kotteas E. Gomatou G, et al. Mol Biol Rep. 2021 Jan;48(1):915-925. doi: 10.1007/s11033-020-06100-3. Epub 2021 Jan 7. Mol Biol Rep. 2021. PMID: 33409716 Review.

4

The Role of Inherited Pathogenic CDKN2A Variants in Susceptibility to Pancreatic Cancer.

Kimura H, Klein AP, Hruban RH, Roberts NJ. Kimura H, et al. Pancreas. 2021 Sep 1;50(8):1123-1130. doi: 10.1097/MPA.0000000000001888. Pancreas. 2021. PMID: 34714275 Free PMC article. Review.

5

Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors.

Cai Z, Wang J, Li Y, Shi Q, Jin L, Li S, Zhu M, Wang Q, Wong LL, Yang W, Lai H, Gong C, Yao Y, Liu Y, Zhang J, Yao H, Liu Q. Cai Z, et al. Sci China Life Sci. 2023 Jan;66(1):94-109. doi: 10.1007/s11427-021-2140-8. Epub 2022 Aug 11. Sci China Life Sci. 2023. PMID: 35982377

6

Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies.

Ozyurt R, Ozpolat B. Ozyurt R, et al. Cancers (Basel). 2022 Oct 24;14(21):5206. doi: 10.3390/cancers14215206. Cancers (Basel). 2022. PMID: 36358625 Free PMC article. Review.

7

Mechanisms and Implications of CDK4/6 Inhibitors for the Treatment of NSCLC.

Zhang J, Xu D, Zhou Y, Zhu Z, Yang X. Zhang J, et al. Front Oncol. 2021 Jul 30;11:676041. doi: 10.3389/fonc.2021.676041. eCollection 2021. Front Oncol. 2021. PMID: 34395246 Free PMC article. Review.

8

Therapeutic potential of CDK4/6 inhibitors in renal cell carcinoma.

Sager RA, Backe SJ, Ahanin E, Smith G, Nsouli I, Woodford MR, Bratslavsky G, Bourboulia D, Mollapour M. Sager RA, et al. Nat Rev Urol. 2022 May;19(5):305-320. doi: 10.1038/s41585-022-00571-8. Epub 2022 Mar 9. Nat Rev Urol. 2022. PMID: 35264774 Free PMC article. Review.

9

The Role of Cavin3 in the Progression of Lung Cancer and Its Mechanism.

Sun G, Ni K. Sun G, et al. Biomed Res Int. 2020 Apr 14;2020:6364801. doi: 10.1155/2020/6364801. eCollection 2020. Biomed Res Int. 2020. PMID: 32352004 Free PMC article.

10

CDK4/6 inhibition alone and in combination for non-small cell lung cancer.

Pacheco J, Schenk E. Pacheco J, et al. Oncotarget. 2019 Jan 18;10(6):618-619. doi: 10.18632/oncotarget.26545. eCollection 2019 Jan 18. Oncotarget. 2019. PMID: 30774754 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results